CytRx Co. (NASDAQ:CYTR)’s share price dropped 15.2% during mid-day trading on Monday . The company traded as low as $1.71 and last traded at $1.79. Approximately 1,444,290 shares traded hands during mid-day trading, an increase of 314% from the average daily volume of 348,670 shares. The stock had previously closed at $2.11.
Separately, ValuEngine lowered CytRx from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st.
The stock has a market capitalization of $59.16, a P/E ratio of -1.01 and a beta of 2.25.
A hedge fund recently raised its stake in CytRx stock. Vanguard Group Inc. raised its position in shares of CytRx Co. (NASDAQ:CYTR) by 53.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,823,123 shares of the biotechnology company’s stock after purchasing an additional 1,689,874 shares during the quarter. Vanguard Group Inc. owned about 3.17% of CytRx worth $3,024,000 as of its most recent SEC filing. 6.22% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “CytRx (CYTR) Shares Down 15.2%” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3279084/cytrx-cytr-shares-down-15-2.html.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.